(0.12%) 5 254.71 points
(0.05%) 39 780 points
(0.03%) 16 405 points
(1.68%) $82.72
(0.52%) $1.727
(0.99%) $2 234.60
(0.63%) $24.91
(1.37%) $922.15
(0.27%) $0.926
(0.70%) $10.84
(0.07%) $0.792
(0.22%) $92.64
@ $4.10
Issued: 14 Feb 2024 @ 09:30
Return: -6.83%
Previous signal: Feb 13 - 09:30
Previous signal:
Return: -0.93 %
Live Chart Being Loaded With Signals
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors...
Stats | |
---|---|
Today's Volume | 192 200 |
Average Volume | 683 475 |
Market Cap | 84.77M |
EPS | $0 ( 2024-03-27 ) |
Next earnings date | ( $-0.440 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.00 |
ATR14 | $0.0100 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-03 | Brady Stephen R | Buy | 250 000 | Employee Stock Option (right to buy) |
2024-01-03 | Whiting Samuel | Buy | 100 000 | Employee Stock Option (right to buy) |
2024-01-03 | Trojanowski Justin | Buy | 26 500 | Employee Stock Option (right to buy) |
2024-01-03 | Maestas Nicholas | Buy | 40 000 | Employee Stock Option (right to buy) |
2023-10-11 | Brady Stephen R | Buy | 725 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
99.68 |
Last 85 transactions |
Buy: 12 322 880 | Sell: 50 340 |
Volume Correlation
Tempest Therapeutics, Correlation
10 Most Negative Correlations | |
---|---|
RAVN | -0.856 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Tempest Therapeutics, Correlation - Currency/Commodity
Tempest Therapeutics, Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-381 000 (0.00 %) |
EPS: | $-1.910 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-85 000.00 (0.00 %) |
EPS: | $-0.350 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-510 000 (0.00 %) |
EPS: | $-0.480 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-497 000 (0.00 %) |
EPS: | $-0.540 |
Financial Reports:
No articles found.
Tempest Therapeutics,
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators